Patents Issued in August 9, 2018
  • Publication number: 20180221273
    Abstract: Methods and compositions for the treatment of pain associated with inflammation in a patient by transdermal delivery of antioxidant to increase glucose uptake and anti-inflammatory cytokines that act to reduce pain.
    Type: Application
    Filed: March 19, 2018
    Publication date: August 9, 2018
    Inventor: KENNETH RUSSELL
  • Publication number: 20180221274
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Application
    Filed: October 13, 2017
    Publication date: August 9, 2018
    Inventor: Alan Meyer
  • Publication number: 20180221275
    Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 9, 2018
    Inventors: Feng Gao, Frank Scott Atchley, Gregory James Griscik, Christopher Joseph DiNovi, Phillip M. Hulan, Diane L. Gee, Gerd Kobal
  • Publication number: 20180221276
    Abstract: A wellness drink is disclosed comprising a mixture of apple cider vinegar, aloe vera, lemon juice, honey, olive oil and at least two spices selected from cayenne pepper, cinnamon, turmeric and ginger. The wellness drink may be high pressure processed to cold pasteurize the drink and then refrigerated and bottled. The typical ten ounce serving for an adult may be taken in the morning with breakfast. The drink may be sold comprising the liquid and spice ingredients without the water to save weight and then mixed with pure water. If taken on a regular basis, the wellness drink may reduce abdominal pain, belching and bloating and induce weight loss and a general sense of well-being. The drink tastes like apple cider with added spices and has a dark yellow orange color. Other forms include capsule, a tea bag, a spice pack and a pill.
    Type: Application
    Filed: February 7, 2017
    Publication date: August 9, 2018
    Applicant: Drink NOVE, LLC
    Inventors: Chris V. Malham, Natalie Dawn Malham
  • Publication number: 20180221277
    Abstract: The invention generally relates to the field of drug delivery. In particular, the invention relates to amphiphilic dendron-coils, micelles thereof and their use for the transdermal delivery of drugs.
    Type: Application
    Filed: November 8, 2017
    Publication date: August 9, 2018
    Inventors: Seungpyo Hong, Yang Yang
  • Publication number: 20180221278
    Abstract: The present invention provides a sustained release formulation of an active pharmaceutical ingredient (“API”). In particular, the sustained release formulation is adapted for topical administration or administration via injection and comprises a nanoemulsion of oil-in-water. In some embodiments, the API is an ophthalmic API. The present invention also provides a method for treating an eye disorder using a sustained release formulation. In one particular embodiment, the invention provides methods for treating dry eye syndrome using a sustained release formulation comprising a nanoemulsion of oil-in-water and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof.
    Type: Application
    Filed: April 3, 2018
    Publication date: August 9, 2018
    Applicant: Ocugen, Inc.
    Inventors: Rasappa Arumugham, Arun K. Upadhyay
  • Publication number: 20180221279
    Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Pieter Cullis, Marcel Bally, Marco Ciufolini, Norbert Maurer, Igor Jigaltsev
  • Publication number: 20180221280
    Abstract: Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 9, 2018
    Inventors: Karine Fabio, Joseph J. Guarneri, Kieran Curley, Marshall L. Grant, Andrea Leone-Bay
  • Publication number: 20180221281
    Abstract: Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template.
    Type: Application
    Filed: January 16, 2018
    Publication date: August 9, 2018
    Applicant: AKINA, INC.
    Inventors: Kinam Park, Ghanashyam S. Acharya, Haesun Park
  • Publication number: 20180221282
    Abstract: A process for drying a spray dried dispersion, comprising: a) providing a spray-dried dispersion comprising particles wherein the particles comprise an active agent and a polymer and optionally one or more surfactants, the dispersion having an average particle diameter of less than about 100 m; b) blending an amount of silicon dioxide with the dispersion to form a dispersion-silicon dioxide blend, wherein the amount of silicon dioxide relative to the amount of dispersion is between about 0.5 and 2.0% by weight; c) drying the blend with a secondary dryer.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yung-Chi Lee, David Harris, Justin David Moser, Michael McNevin, Amber Broadbent, Robert Hall, Ari Ericson
  • Publication number: 20180221283
    Abstract: The present application relates to a method for the preparation of a nanosuspension comprising nanoparticles of at least one natural material and an extract of at least one natural material, wherein the method comprises the steps of providing particles of at least one natural material having a particle size (D100) of less than 320 ?m; providing an extract of at least one natural material; dispersing said particles of at least one natural material and said extract of at least one natural material in a solvent; and milling the dispersion to a particle size (D90) of below 1000 nm (D90<1000 nm). Furthermore, the present application also relates to a nanosuspension prepared according to said method, and the use of such nanosuspension for the preparation of a medicament and/or nutritional supplement.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 9, 2018
    Applicant: Apurano Life sciences GmbH
    Inventor: Werner BRAND
  • Publication number: 20180221284
    Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Inventors: Henrik NILSSON, Roland RUPP
  • Publication number: 20180221285
    Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
    Type: Application
    Filed: March 23, 2018
    Publication date: August 9, 2018
    Inventors: Indrajit Ghosh, Jia-Ai Zhang
  • Publication number: 20180221286
    Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and/or right colon of a human subject.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 9, 2018
    Inventors: Mohan Kabadi, Jerome J. Schentag
  • Publication number: 20180221287
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Applicant: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Publication number: 20180221288
    Abstract: A capsule excellent in enteric property with the assumption that gelatin is used as a main base material of the capsule coating. An alkali-treated gelatin and carrageenan are contained as base materials of the capsule coating. In the gastric (aqueous) environment, the alkali-treated gelatin which is positively (+) charged coexists with the carrageenan which is negatively (?) charged, and amino groups (NH4+) in the gelatin react with sulfate groups (SO3?) in the carrageenan so that the capsule coating is insolubilized. On the other hand, in the intestinal (aqueous) environment, the alkali-treated gelatin which is negatively (?) charged coexists with the carrageenan which is negatively (?) charged, and the amino groups (NH4+) in the gelatin are repulsive to the sulfate groups (SO3?) in the carrageenan so that the capsule coating quickly disintegrates and dissolves.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 9, 2018
    Applicant: SUNSHO PHARMACEUTICAL CO. LTD
    Inventors: Takayuki FUKASAWA, Kenichi KOYAMA, Tomoya SUZUKI
  • Publication number: 20180221289
    Abstract: In one aspect, the invention provides therapeutic agent nanoparticles coated with cholesteryl esters, formulations of the nanoparticles suitable for injection, methods for administering therapeutic agents and for treating diseases and conditions treatable by the therapeutic agents using the formulations. In a related aspect, the invention provides synthetic high density lipoprotein nanoparticles useful for therapeutic agent delivery, and methods for their preparation and use.
    Type: Application
    Filed: August 8, 2016
    Publication date: August 9, 2018
    Applicant: Autotelic LLC
    Inventor: Vuong Trieu
  • Publication number: 20180221290
    Abstract: The present invention relates to a method for preparing a stable extended release suspension composition comprising multiple coated cores of an active ingredient by using a suspension base, wherein the suspension base ensures substantially similar in-vitro dissolution release profile of the active ingredient upon storage of the suspension compositions for at least seven days.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Romi Barat SINGH, Ashish KUMAR, Rajesh Srikrishan SHEAR, Satish Kumar JAIN, Paras P. JAIN
  • Publication number: 20180221291
    Abstract: The present invention provides a process for forming Janus particles. The novel application of the Janus particles is also disclosed in the present invention. In particular, the Janus particles have an average diameter less than 10 nm and a peak between 2850 and 2921 cm?1 in Fourier transform infrared spectrum.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Huan-Tsung Chang, Tzu-Heng Chen, Arun Prakash Periasamy
  • Publication number: 20180221292
    Abstract: The present invention provides Janus particles and a novel vesicle. In particular, the novel vesicle comprises a plurality of the Janus particles. The Janus particles have symmetric and asymmetric stretching vibrations of CH2 at about 2920 and 2850 cm?1, each with a shoulder, in Fourier transform infrared spectrum.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Huan-Tsung Chang, Tzu-Heng Chen, Arun Prakash Periasamy
  • Publication number: 20180221293
    Abstract: Mucus penetrating particles (MPPs) include one or more core polymers, one or more therapeutic, prophylactic and/or diagnostic agents; and one or more surface modifying agents. The surface modifying agents coat the surface of the particle in a sufficient density to enhance the diffusion of the modified nanoparticles throughout the mucosa, relative to equivalent nanoparticles that are not surface modified. Nanoparticles can be sufficiently densely coated with poly(ethylene glycol) (PEG) with a molecular weight of from 10 kD to 40 kD or greater coated with a surface density from about 0.1 to about 100 molecules/100 nm2, preferably from about 0.5 to about 50 molecules/100 nm2, more preferably from about 0.9 to about 45 molecules/100 nm2.
    Type: Application
    Filed: October 31, 2016
    Publication date: August 9, 2018
    Inventors: Justin Hanes, Katharina Maisel, Laura Ensign, Richard Cone
  • Publication number: 20180221294
    Abstract: A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.
    Type: Application
    Filed: April 3, 2018
    Publication date: August 9, 2018
    Inventors: Jan-Otto CARLSSON, Anders JOHANSSON, Marten ROOTH
  • Publication number: 20180221295
    Abstract: The present invention relates to electrospun fibres containing: i) a first and a second hydrophilic fibre-forming polymer that is soluble in a hydrophilic solvent, ii) a bioadhesive substance that is slightly soluble in said hydrophilic solvent, iv) a drug substance, wherein the first hydrophilic polymer has a solubility in water at 37° C. that is at least 10 times greater than the solubility in water at 37° C. of the second hydrophilic fibre-forming polymer, and wherein the bioadhesive substance is present in solid form.
    Type: Application
    Filed: January 29, 2018
    Publication date: August 9, 2018
    Applicant: DERMTREAT APS
    Inventors: Jens Hansen, Martin Eduardo Santocildes Romero
  • Publication number: 20180221296
    Abstract: A new method of targeted drug administration to wounds (surgical or traumatic), intrasite (IS), offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing IS medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large IS doses increase risk of toxicity from impurities allowed in drugs given by other routes. Methods are presented for ultrapurification, particularly of endotoxins. Methods are presented for sterile delivery to the wound, to prevent aerosolization, and to homogenize application. Pharmacodynamic parameters make certain drugs advantageous as IS agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an IS medication.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventors: Terrence Fletcher Holekamp, Lawrence Gerard Lenke, Michael Patrick Kelly
  • Publication number: 20180221297
    Abstract: Transdermal drug delivery devices and systems with improved adhesion are disclosed. The transdermal drug delivery devices, or patches, include an integrated overlay that provides a drug-free adhesive perimeter designed to avoid affecting delivery of drug from the device. Also disclosed are methods of manufacturing the transdermal drug delivery devices that include incorporating an integrated overlay onto a TDS patch.
    Type: Application
    Filed: February 2, 2018
    Publication date: August 9, 2018
    Inventor: Kirti H. Valia
  • Publication number: 20180221298
    Abstract: The present invention provides a transdermal patch comprising: a drug-containing layer comprising (R)-dihydroetorphine, or a salt or a hydrate thereof, and a poly(meth)acrylate; and a backing layer.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 9, 2018
    Applicant: Euro-Celtique S.A.
    Inventors: Steve WHITELOCK, Deborah Phyllis HARDING, Helen JOHNSON, Kevin SMITH, Gill MUNDIN
  • Publication number: 20180221299
    Abstract: The present invention provides a transdermal delivery system comprising (R)-dihydroetorphine, or a salt, hydrate or derivative thereof, wherein said system has a rapid onset of (R)-dihydroetorphine plasma concentration characterised by the mean in vivo plasma concentration of (R)-dihydroetorphine achieving at least 50% of its Cmax in less than 20 hours, preferably in less than 18 hours and more preferably in less than 12 hours, after application of the system to the skin of a human subject, e.g. when based on the mean plasma concentration versus time curve.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 9, 2018
    Applicant: EURO-CELTIQUE S.A.
    Inventors: Steve WHITELOCK, Deborah Phyllis HARDING, Helen JOHNSON, Kevin SMITH, Gill MUNDIN
  • Publication number: 20180221300
    Abstract: Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and and C) optionally an additional skin contact layer.
    Type: Application
    Filed: May 20, 2015
    Publication date: August 9, 2018
    Applicants: LTS LOHMANN Therapie-Systeme AG, UCB Pharma GmbH
    Inventors: Marco Emgenbroich, Johannes Josef Leonhard, Kristina Kassner, Aurélia Lappert
  • Publication number: 20180221301
    Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Inventors: Kristin Jackson, Kenneth J. Miller
  • Publication number: 20180221302
    Abstract: The invention provides devices and methods for adjusting particle size in nanoemulsions of fluorocarbons and perfluorocarbons (e.g., perfluoropentane and perfluorohexane) via sonication (e.g., ultrasonication).
    Type: Application
    Filed: August 15, 2016
    Publication date: August 9, 2018
    Inventors: Evan C. Unger, Edmund Marinelli
  • Publication number: 20180221303
    Abstract: Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.
    Type: Application
    Filed: July 19, 2016
    Publication date: August 9, 2018
    Inventor: Guido Grentzmann
  • Publication number: 20180221304
    Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 9, 2018
    Inventors: Andrea Small-Howard, Helen Turner
  • Publication number: 20180221305
    Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Inventor: Lanny Leo Johnson
  • Publication number: 20180221306
    Abstract: Disclosed herein are pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. Also disclosed are methods of treating diseases and/or conditions associated with a cancer, such as prostate cancer with such pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. The disclosed pharmaceutical compositions may provide improved dosage for oral administration to patients in the clinic. The disclosed pharmaceutical compositions may provide improved stability and/or shelf life.
    Type: Application
    Filed: March 15, 2018
    Publication date: August 9, 2018
    Inventors: Per Borgström, Adrian Chrastina, Veronique Baron
  • Publication number: 20180221307
    Abstract: The invention relates to a monolithic pharmaceutical dosage form comprising a hot melt-extruded first segment (S1) and a second segment (S2); wherein the first segment (S1) contains at least a first pharmacologically active ingredient (A1) and/or the second segment (S2) contains at least a second pharmacologically active ingredient (A2); and the segment (S1) and/or the segment (S2) is tamper-resistant and/or exhibits a breaking strength of at least 300 N.
    Type: Application
    Filed: January 30, 2018
    Publication date: August 9, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: ANJA GEIßLER-FICHTNER, Klaus Wening, Lutz Barnscheid, Jana Pätz
  • Publication number: 20180221308
    Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Johannes BARTHOLOMAEUS, Iris ZIEGLER
  • Publication number: 20180221309
    Abstract: Various embodiments disclosed relate to treatment of fungal infections. The present invention provides a method of treating a fungal infection including contacting a fungus including a ?-glucan that is at least partially masked from immune system detection with a therapeutically effective amount of a compound that at least partially unmasks the ?-glucan to increase immunogenicity of the fungus.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 9, 2018
    Inventors: Aaron Kurt Neumann, Harry Craig Pappas, Matthew Graus
  • Publication number: 20180221310
    Abstract: The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 9, 2018
    Inventors: Philippe GUEDAT, Pierre MINIOU
  • Publication number: 20180221311
    Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.
    Type: Application
    Filed: March 31, 2018
    Publication date: August 9, 2018
    Inventors: Carolyn L. TWOMEY, Gareth CLARKE, Samuel ZAIDSPINER
  • Publication number: 20180221312
    Abstract: N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (compound 4), a known chemokine modulator, in combination with colchicine is useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity, interleukin-1 (IL-1) activity, and/or myeloperoxidase (MPO) activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of such diseases/conditions.
    Type: Application
    Filed: September 12, 2017
    Publication date: August 9, 2018
    Inventors: Payal NANAVATI, Johan HOEGSTEDT, Jesse HALL
  • Publication number: 20180221313
    Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.
    Type: Application
    Filed: August 8, 2016
    Publication date: August 9, 2018
    Applicant: Centre National De La Recherche Scientifique (CNRS)
    Inventors: Yves COLIN, Jean-Francois GIRMENS, Olivier HERMINE, Emmanuel HERON, Michel PAQUES
  • Publication number: 20180221314
    Abstract: The present invention relates to oral liquid compositions of guanfacine. The liquid compositions can be immediate release or extended release compositions. The compositions comprise guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition. The liquid compositions can be in the form of ready-to use liquid compositions or reconstituted liquid compositions. It further relates to processes for the preparation of said oral liquid compositions.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Romi Barat SINGH, Kalaiselvan RAMARAJU, Balaram MONDAL, Ashish KUMAR, Suchitra KAUSHIK
  • Publication number: 20180221315
    Abstract: Described herein is a method for treating a medical condition in a patient, the method comprising: administering to a patient in need (thereof a pharmaceutical composition comprising a therapeutically effective amount of (i) a first therapeutic agent which is acamprosate or a pharmaceutically acceptable salt thereof and (ii) a second therapeutic agent which is D-cycloserine, a salt of D-cycloserine, an ester of D-cycloserine, an alkylated D-cycloserine, or a precursor of D-cycloserine.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 9, 2018
    Inventors: Steven L. JOHNS, Craig A. ERICKSON
  • Publication number: 20180221316
    Abstract: This document provides methods and materials for reducing the degree of damage to tissue transplanted into a mammal following transplantation. For example, methods and materials for using abscisic acid to reduce tissue damage to vascularized tissue transplanted into a mammal following reperfusion of that vascularized tissue are provided.
    Type: Application
    Filed: August 3, 2016
    Publication date: August 9, 2018
    Inventor: Agnes NAGY
  • Publication number: 20180221317
    Abstract: The invention relates to a composition for the treatment of superficial lesions, in particular skin lesions, mucous membrane lesions and/or nail lesions, an applicator comprising such a composition and the use of such a composition. The composition comprises an effective amount of trichloroacetic acid, at least one thickener, and at a physiologically acceptable solvent. And is effective against a plethora of superficial lesions selected from the group consisting of viral warts, verrucae, water warts (molluscum contagiosum), corns and calluses, and skin hyperpigmentation: age spots, solar lentigo, senial lentigo, acne, keratosis pilaris, actinic keratosis, mouth ulcers (canker sores), cold sores, ingrown toenails, onychomycosis, eyelid xanthelasma.
    Type: Application
    Filed: April 3, 2018
    Publication date: August 9, 2018
    Applicant: Progressare Medinvest B.V.
    Inventors: Maikel HENDRIKS, Pieternella BOUTER, Katarzyna KOLODZIEJ
  • Publication number: 20180221318
    Abstract: The present invention provides compositions, methods and kits for treating acne and other skin conditions influenced by P. acnes, which combine administration of low levels of at least one C2 to C5 polycarboxylic acid and blue light to skin in need of treatment for such conditions.
    Type: Application
    Filed: February 8, 2017
    Publication date: August 9, 2018
    Inventors: Julie Marie Bianchini, Kimberly A. Capone, Kelly A. Dunn, Ali Fassih, Davide Miksa, Barry Setiawan, Michael D. Southall, Liliam A. Moreira
  • Publication number: 20180221319
    Abstract: Methods of treating a seizure disorder with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of a seizure disorder. Methods of treating Prader-Willi syndrome with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of Prader-Willi syndrome.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventor: Matthew DURING
  • Publication number: 20180221320
    Abstract: Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.
    Type: Application
    Filed: August 16, 2016
    Publication date: August 9, 2018
    Inventors: Christopher F. Rose, Franck Rousseau
  • Publication number: 20180221321
    Abstract: The invention relates to methods and related compositions for enhancing cancer therapy and in particular glutaminase inhibitor therapy. The methods involve methods for identifying patients susceptible to glutaminase inhibitor therapy as well as sensitizing patients to glutaminase inhibitor therapy.
    Type: Application
    Filed: February 6, 2018
    Publication date: August 9, 2018
    Applicant: Massachusetts Institute of Technology
    Inventors: Alexander Muir, Matthew Vander Heiden, Laura Danai, Dan Yi Gui
  • Publication number: 20180221322
    Abstract: Embodiments of the present invention are directed to methods, apparatus and articles of manufacture that feature omega-3 fatty acids co-processed with flavonoid and lipophilic antioxidants for improved stability.
    Type: Application
    Filed: November 22, 2017
    Publication date: August 9, 2018
    Inventors: Bo Martinsen, Leif Andreas Riege